For Investors

Investor Relations

Latest Press Releases

All Press Releases
Date Title
June 11, 2021
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
June 10, 2021
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
June 7, 2021
Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
May 25, 2021
Novan Announces 1-for-10 Reverse Stock Split

Recent SEC Filings

All SEC Filings

Upcoming Events

More 
More events are coming soon.

Stock Information

more

Exchange
Volume
Today's Open
Previous Close

Data as of Jun 14, 2021 5:45 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

June 1, 2021
October 21, 2016

Corporate Governance

Click here to view our Corporate Governance information.

IR & Media Contact

Information Request

Click here to request information.

Presentation

More
May 14, 2021

Annual Report

More
April 30, 2021

Analyst Coverage

more
Firm Analyst
HC Wainwright & Co.
Oren Livnat, CFA
Roth Capital Partners
Jonathan Aschoff Ph.D.
Zacks Small-Cap Research
John D. Vandermosten, CFA

Novan, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Novan, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Novan, Inc. or its management. Novan, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Transfer Agent

E-mail Alerts

  • Sign up here to get latest notifications whenever Novan inc. posts new information to the site.